NanoViricides, Inc.(NYSE Amex Equities : NNVC)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-0.46%||8.65||0.7%||$604.67m|
|GILD||Gilead Sciences, Inc.||-0.70%||71.19||1.0%||$455.28m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.18%||638.90||2.7%||$418.56m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.80%||183.61||1.9%||$245.25m|
|ISEE||IVERIC bio, Inc.||0.86%||16.37||0.0%||$193.25m|
|DVAX||Dynavax Technologies Corp.||1.17%||19.83||5.7%||$156.65m|
|LIFE||aTyr Pharma, Inc.||-17.87%||10.25||2.1%||$156.36m|
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.